Early tumor shrinkage and depth of response with first-line panitumumab or bevacizumab and mFOLFOX treatment in PARADIGM
ANNALS OF ONCOLOGY(2023)
Abstract
The PARADIGM primary analysis demonstrated that panitumumab (PAN) significantly improved OS vs bevacizumab (BEV) with mFOLFOX6 in RAS WT and left-sided metastatic colorectal cancer (mCRC). Early tumor shrinkage (ETS) and depth of response (DpR) are on-treatment prognostic factors related to favorable OS and PFS in mCRC chemotherapy. We report ETS and DpR and the correlation with OS and PFS in patients (pts) with RAS WT mCRC from PARADIGM.
MoreTranslated text
Key words
early tumor shrinkage,bevacizumab,mfolfox treatment,first-line
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined